However, in vitro analyses on prostate cancer showed that CD26 has a suppressor function on tumor progression by blocking the basic fibroblast growth factor signaling pathway (24) or suppressing the chemotactic migration of tumor cells (25). This evidence concerns the gene FGF2 and prostate carcinoma.